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ABSTRACT 
 
USD Honors Thesis: 
Dementia: types, what they are and how they differ 
 
Jessica Schnetzer 
 
Director: Ranelle Nissen, PhD, OTR/L 
 
 
Dementia: types, what they are and how they differ centers on the known and unknown 
complexities of dementia. Dementia is a very complex cognitive disease that consumes 
the brain, an organ of which we know very little about. Even so, this common disorder is 
actively being researched and is the topic of special interest of this thesis research. 
Described are Alzheimer’s disease, Creutzfeldt-Jakob disease, Frontotemporal dementia, 
Huntington’s disease, Korsakoff’s syndrome, Lewy body dementia, Parkinson’s 
dementia, and Vascular dementia, focusing on what they are, their specific risks, 
diagnosis, treatment, and their differing progressions. Guidance of this study provided by 
thesis director Ranelle Nissen, who studies dementia and is a professor at USD. The 
remaining two thesis committee members are Mary H. Schmitz, Director of the memory 
unit and former director of activities at Grand Living at Lake Lorraine in Sioux Falls, and 
Joy Backes, Director of health and wellness, also, at Grand Living at Lake Lorraine; all 
of whom have extensive dementia experience and are reliable resources and mentors 
during this dementia thesis process. 
 
 
KEYWORDS: dementia, cognitive disease, disorder, Ranelle Nissen, Mary H. Schmitz, 
Joy Backes, Alzheimer’s disease, Creutzfeldt-Jakob disease, Frontotemporal dementia, 
Huntington’s disease, Korsakoff’s syndrome, Lewy body dementia, Parkinson’s 
dementia, Vascular dementia 
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CHAPTER ONE 
ALZHEIMER’S DISEASE 
What it is and how it differs 
 Since 1910, the term ‘Alzheimer’s disease’ has been used to describe this illness, 
named after Alois Alzheimer (Yang et al., 2016). However, there has been a record of 
dementia research specific to this disease before the name was assigned. A Swiss 
researcher named Otto Ludwig Binswanger (1852-1929) did research on neurosyphilis, a 
causing factor of dementia, along with Dr. Alois Alzheimer (Yang et al., 2016). He 
described numerous occurrences of vascular dementia in 1894 and in his report, the term 
‘presenile dementia’ was first mentioned (Yang et al., 2016). Later, in 1910, a German 
doctor by the name of Emil Kraepelin (1856-1926) developed two classifications of 
dementia, splitting its descriptions into senile dementia and presenile dementia (Yang et 
al., 2016). He was then the first to title the disease as ‘Alzheimer’s disease’ after Alois 
Alzheimer, who discovered pathological features of presenile dementia while working as 
the namesake’s student (Yang et al., 2016).  
Alzheimer’s disease is the most common form of dementia. Alzheimer’s disease 
has two defining factors that separate it from the rest, which are amyloid plaques and 
neurofibrillary tangles (Ballard et al., 2011). The key component of neurofibrillary 
tangles is a microtubule-associated protein termed tau (Ballard et al., 2011). The amyloid 
cascade hypothesis suggests that modifications in tau and resulting neurofibrillary tangle 
formations are caused by toxic concentrations of Aβ. Several hypotheses have been 
offered on why this occurs; however, the pathways connecting Aß and tau are not plainly 
understood (Ballard et al., 2011). 
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Specific Risks 
 
 Of the 24 million people with dementia, most have been diagnosed with 
Alzheimer’s disease, the most common form of dementia (Ballard et al., 2011). 
Alzheimer’s has such a high occurrence that it even outnumbers stroke, cardiovascular 
disease, and cancer events in people over 60 years of age (Ballard et al., 2011). 
Alzheimer’s disease has many risk factors, the most common of which are genetics and 
environmental factors (Ballard et al., 2011). The gene with the highest risk factor of 
Alzheimer’s disease is the APOE gene, which is involved with the transfer of cholesterols 
and can increase a person’s risk of diagnosis by 3-10 times (Ballard et al., 2011).  
Environmental factors include lifestyle risks (Obesity, smoking, physical activity, 
cognitive reserve, alcohol) and some medical conditions (Midlife hypertension, stroke, 
diabetes, midlife hypercholesterolemia) (Ballard et al., 2011). However, because many of 
the risk factors come from a person’s lifestyle, a diagnosis of Alzheimer’s disease can be 
prevented/ prolonged with appropriate lifestyle changes (Ballard et al., 2011). 
 
Diagnosis and Treatment 
 Up until recent years, the diagnosis of Alzheimer’s disease was only definitively 
possible post mortem (Ballard et al., 2011). With increasing knowledge in neuroimaging 
technologies and clinical diagnosis, earlier diagnoses have become possible (Ballard et 
al., 2011).  When considering the clinical aspects of diagnosis, the patient’s symptoms 
are assessed, as well as their family history, which plays a great role in diagnosis (Ballard 
et al., 2011).  A neuropsychological assessment evaluates certain aspects of possible 
cognitive impairment, such as whether social, occupational, or other instrumental 
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functions have been affected (Ballard et al., 2011).  There are specific criteria that can be 
followed in such assessments: NINCDS-ADRDA (National Institute of Neurological and 
Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders 
Association), for example, has over 80% specificity for separating an Alzheimer’s case 
from a non-dementia case (Ballard et al., 2011). However, this criterion has proven less 
effective when differentiating between a possible Alzheimer’s diagnosis and other 
dementia possibilities (Ballard et al., 2011).  Neuroimaging is very important when this 
comes into play, through which doctors can measure the brain volume of specific 
structures in the brain (Ballard et al., 2011).  The hippocampus, for example, is an 
important focus when diagnosing Alzheimer’s disease, and can help monitor the 
progression of the disease, as well as concluding an Alzheimer’s diagnosis (Ballard et al., 
2011). A neuroimaging biomarker assessment is very important in diagnosing a patient, 
especially when aligned with clinical symptoms (Ballard et al., 2011).  There is a wide 
range of treatments available to lessen the clinical symptoms of Alzheimer’s disease; 
however, there are no available cures or disease-modifying treatments (Ballard et al., 
2011). Researchers are working to develop treatments that could potentially slow the 
progression of the disease through the study of the pathogenesis of brain atrophy in 
patients (Ballard et al., 2011).  Since there are not treatments available to reverse or slow 
the progression of Alzheimer’s disease, early diagnosis is key (Ballard et al., 2011).   
 
 
Progression 
 Neuronal dysfunction is caused by “amyloid cascade,” which is a hypothesis 
proposing that deposition of amyloid β (Aβ) triggers neuronal dysfunction and death in 
the brain (Ballard et al., 2011, p. 1019). This leads to the constant progression of 
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Alzheimer’s disease in patients throughout all stages of the disease (Ballard et al., 2011). 
Alzheimer’s disease is extremely common in the dementia field and is trademarked by 
progressive memory loss. When a patient first develops the disease, he or she will 
experience very short-term memory loss, which will continue to expand to longer-term 
memory loss as the disease progresses. Though post-mortem measurements of 
deterioration of the brain in Alzheimer’s patients can often directly coordinate with the 
patient’s degree of memory loss, this is not the case in some patients, which is where 
more research is to be conducted on whether or not these are misdiagnosed, or if there are 
other aspects of Alzheimer’s disease that have gone unnoticed in previous studies 
(Ballard et al., 2011). 
 
CHAPTER TWO 
CREUTZFELDT-JAKOB DISEASE 
What it is and how it differs 
 Discovered in the 1920s by German neurologists Creutzfeldt and Jakob, 
Creutzfeldt-Jakob disease (CJD) is a rare form of progressive dementia that’s onset is far 
different from any other form of dementia discussed in this review (Tyler, 2003). CJD is 
associated with a poorly understood transmissible agent and is an uncommon but 
habitually fatal degenerative disease of the central nervous system (Centers for Biologics 
Evaluation Research, 2002). The mechanism of contraction and manifestation of this 
disease is poorly understood. Research suggests that CJD may be acquired by exogenous 
exposure to some sort of infectious material, or may perhaps be hereditary, caused by a 
genetic mutation of the prion protein gene (Centers for Biologics Evaluation Research, 
2002). There are two types of this disease: new variant Creutzfeldt-Jakob disease 
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(nvCJD) and the general CJD (vCJD), which differ in progression and the average age of 
onset, as well as neuropathologic features (Centers for Biologics Evaluation Research, 
2002). These variations have been set apart from other forms of dementia, too, because of 
their association with bovine spongiform encephalopathy (BSE, also known as “mad cow 
disease”), which was introduced after the 1980s-1990s epidemic of BSE in the U.K 
(Biologics Evaluation Research, 2002). 
 
Specific Risks 
 Clinical symptoms of Creutzfeldt-Jakob’s disease occur due to either genetic or 
sporadic events. Genetic occurrences result from the aggregation of pathologic isoform 
(PrPCJD) in a common protein called the prion protein (PrPC) (Tyler, 2003). Sporadic 
occurrences result from abnormal proteins found in the cerebrospinal fluid, most 
commonly the 14-3-3 protein (Tyler, 2003). Cruetzfeldt-Jakob’s disease is much rarer 
than other diseases with similar symptoms, having a prevalence rate of 1 in every one 
million (Tyler, 2003). It became popular to the public during the epidemic of BSE, where 
a largely disproportionate amount of people developed cases of new variant Creutzfeldt-
Jakob disease, leading researchers to believe that this condition can also be infectious, as 
85% of cases recorded have been listed as sporadic (Tyler, 2003). The compact amount 
of irregular prion protein present in vCJD lymphoid tissues issued concerns that the 
spread of vCJD by blood could be a larger threat than for genetically-issued CJD (Centers 
for Biologics Evaluation Research, 2002). Limited experimental or epidemiological 
analyses of vCJD transmissibility by blood or plasma have been published, and it is 
unclear whether human blood can transmit the vCJD agent (Centers for Biologics 
Evaluation Research, 2002). As a result of this concern, there are new limits on who can 
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and cannot donate plasma as an extra precaution when dealing with those who could have 
been exposed (Centers for Biologics Evaluation Research, 2002). 
Diagnosis and Treatment 
 Like many other forms of dementia, neuropathologic testing is the only way to 
confirm a definitive diagnosis of vCJD, as there are many types of florid plaques possible 
in diagnosis, which cannot be confirmed clinically (Tyler, 2003).  When looking at the 
basal ganglia and thalamus during a diagnosis, spongiform change should be evident with 
little distribution in the cerebral cortex of the patient (Tyler, 2003).  There may also be a 
dense accumulation of abnormal prion proteins, which are specifically shown to be 
common in the cerebrum and cerebellum in a person with vCJD (Tyler, 2003).   A final 
diagnosis is confirmed by the identification of spongiform degeneration, neuronal loss, 
and astrogliosis of brain tissue (Centers for Biologics Evaluation Research, 2002). Of 
course, a patient is not diagnosed in most cases until clinical symptoms become apparent. 
These may include cognitive impairment, pain and paresthesias, dysarthria, and changes 
in gait (Centers for Biologics Evaluation Research, 2002).  
 Immunodiagnosis can also be done through antibody analysis, which can 
recognize both normal and pathologic isoforms of PrP (Centers for Biologics Evaluation 
Research, 2002). This is done by first providing a pretreatment that causes the antibodies 
to break down the normal proteins while leaving the pathologic isoforms intact (Centers 
for Biologics Evaluation Research, 2002). There are simple tonsil biopsies that can be 
done to diagnose nvCJD, and there is research that suggests the possibility of nasal 
biopsies being able to diagnose sporadic CJD, as well (Centers for Biologics Evaluation 
Research, 2002). There is not much successful research published for the treatment of 
CJD disease; however, medications can alleviate symptoms that develop after the 
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infection subsides. Scientists deem it possible to interfere with the conversion of PrPC to 
its pathologic state, which could potentially become a therapeutic target for variants of 
this disease in the future (Centers for Biologics Evaluation Research, 2002). 
 
Progression 
 
 Creutzfeldt-Jakob disease progresses much more rapidly than most other cases of 
dementia, often worsening at a daily pace (Centers for Biologics Evaluation Research, 
2002). Common symptoms of early CJD include memory loss, visual hallucinations, 
varying types of delusions, and intense emotional and mood changes (Centers for 
Biologics Evaluation Research, 2002). As the disease progresses, a patient may 
experience “jerking” motor symptoms of the face and limbs, and develop a “startle 
myoclonus” upon stimulation (Centers for Biologics Evaluation Research, 2002, p. 1). 
The new-variant type of this disease varies greatly from sporadic cases, most importantly 
differing in age of onset. The average age of onset of the new-variant type is just 26 years 
of age, whereas sporadic cases of Creutzfeldt-Jakob disease occur almost four decades 
later (Centers for Biologics Evaluation Research, 2002). In nvCJD, symptoms of 
dysphoria, irritability, anxiety, apathy, energy loss, insomnia, and social withdrawal are 
common in the early to middle stages, and worsen until the mute phase (Centers for 
Biologics Evaluation Research, 2002). The mute phase is typically seen in the late 
progression of Creutzfeldt-Jakob disease, which lasts until the patient dies (Centers for 
Biologics Evaluation Research, 2002). 
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CHAPTER THREE 
 
FRONTOTEMPORAL DEMENTIA 
 
 
What it is and how it differs 
 Arnold Pick, a Czech neurologist, first discovered Frontotemporal dementia 
(FTD) in 1892. His patient was described to have “progressive deterioration of language 
associated with left temporal lobe atrophy,” which would later be termed svPPA, also 
known as semantic variant primary progressive aphasia (Olney et al., 2017, p. 340). 
Decades later, Frontotemporal dementia research resurfaced upon the publishing of 
research conducted by Delay, Brion, and Escourolle. This French group of researchers 
published a seminal paper highlighting the clinical and neuropathologic differences 
between Alzheimer's and Pick’s disease (Olney, 2017). Pick’s disease was defined to 
include frontotemporal atrophy (not including that of the posterior lobes) with histology 
that showed inflated cells and cortical-subcortical gliosis. Considering clinical aspects of 
the disease, symptoms included increased changes in behavior, lack of insight, and lack 
of apraxia and agnosia. These histological and clinical findings can be easily compared to 
Alzheimer’s dementia, as it includes diffuse cerebral atrophy and displays neurofibrillary 
tangles as well as senile plaques, not to mention the overt presense of agnosia and 
apraxia. Because of its evident variance, Constantinidis and colleagues divided Pick’s 
disease into three different subtypes much later, in 1974 (Olney, 2017). Interestingly, 
only one of the three subtypes displayed the “classic” Pick bodies, signifying that Pick 
bodies are not necessary in concluding a diagnosis of Pick’s disease (Olney, 2017). 
Currently, FTD comprises clinical disorders that include changes in behavior, language, 
executive control, and motor symptoms (Olney et al., 2017). The three core 
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Frontotemporal spectrum disorders discussed are behavioral variant FTD (bvFTD), 
nonfluent/agrammatic variant primary progressive aphasia (nfvPPA), and semantic 
variant PPA (svPPA) (Olney et al., 2017). FTD is a heterogeneous disorder that involves 
a range of specific phenotypes in association with neuropathologic substrates of 
frontotemporal lobar degeneration (FTLD) including, but not limited to, FTLD-tau, 
FTLD-TDP, and FTLD-FET (Olney et al., 2017).  
 
Specific Risks 
 
 Every year, an estimated 1.61 to 4.1 per every 100,000 people in the United States 
are diagnosed with Frontotemporal dementia leading to the presence of somewhere 
between 20,000 to 30,000 people with this disease in the country at one time (Olney et 
al., 2017). Further, Frontotemporal dementia is the second most common dementia in 
people who are under the age of 65, following Alzheimer’s disease (Olney et al., 2017). 
The typical age range for a Frontotemporal dementia diagnosis is between the ages of 45 
and 65, with rare outliers outside this age span (Olney et al., 2017). Overall, gender does 
not seem to be a risk factor in the likelihood of developing this disease as supported by a 
multitude of statistics (Olney et al., 2017). The most common form of Frontotemporal 
dementia is bvFTD, which accounts for a staggering 60% of cases, with the remaining 
40% accounting for various language variants of Frontotemporal dementia (Olney et al., 
2017). However, this disease is presumably under diagnosed due to its overlapping 
symptoms with a high number of other psychiatric disorders (Olney et al., 2017). 
Genetics are also a sizeable risk factor of developing this disease, with 40% of 
Frontotemporal dementia cases having strong genetic ties (Olney et al., 2017). This 
includes those having a family history of symptoms associated with Frontotemporal 
dementia while at least 10% of cases have an autosomal dominant inheritance pattern 
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(Olney et al., 2017). In fact, FTD-MND is the most heritable clinical syndrome with 
C9ORF72, MAPT, and GRN being the most common genes associated with 
Frontotemporal dementia (Olney et al., 2017).  
 
Diagnosis and Treatment 
 
 When diagnosing frontotemporal dementia, priorities include assessing a patient’s 
medical and clinical histories in order to pinpoint which area of the brain is affected 
(Olney et al., 2017). This is to be done as early on as possible, as new clinical symptoms 
develop with further atrophic progression of the disease (Olney et al., 2017). Various 
neuroimaging can further support a Frontotemporal dementia diagnosis; however, this is 
not always done (Olney et al., 2017). A clinical diagnosis for Frontotemporal dementia 
includes assessment of possible impaired confrontation naming, impaired single word 
comprehension, impaired object knowledge, or any surface dyslexia or dysgraphia (Olney 
et al., 2017). There are no approved treatments for FTD, so a prescribed treatment is 
often recommended based on the patient’s symptoms and progression (Olney et al., 
2017). Many medications have been tested for this condition,, including Alzheimer’s 
medications, acetylcholinesterase inhibitors, and Mamantine, which have all proved to be 
uneffective in treating symptoms (Olney et al., 2017). The most effective drug on the 
market for FTD has been found to be limited to serotonin uptake inhibitors, such as 
Trazadone, which can help to lessen a patient’s symptoms (Olney et al., 2017). 
Antipsychotics are pushed for some symptoms of FTD, but should be used with caution, 
as they come with side effects that vary from person to person and is highly understudied 
for use in the elderly (Olney et al., 2017). As far as nonpharmaceutical therapies go, 
exercise has been proven to show improvement for those patients who can safely endure 
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it, and speech therapy is typically effective in the early stages of the disease (Olney et al., 
2017). 
Progression 
 
 The earliest stages in the progression of Frontotemporal dementia are mild and 
can vary depending on where deterioration occurs. A patient often experiences changes in 
behavior, personality, emotion, and executive function such as disinhibition, new 
compulsions, dietary changes, and symptoms like apathy/lack of empathy are common 
(Olney et al., 2017). A common first symptom of frontotemporal dementia is difficulty 
with word-finding, or not being able to associate a word with an idea (Olney et al., 2017). 
Many of these early symptoms are similar to those seen in psychiatric illness, so in the 
early stages, a patient is at risk of misdiagnosis (Olney et al., 2017). Symptoms that are 
associated with dysfunction are caused by deterioration in the paralimbic areas of the 
brain. These can include the medial frontal, orbital frontal, anterior cingulate, and 
frontoinsular cortices (Olney et al., 2017). As the disease progresses, symptoms of 
disinhibition begin to manifest. These can include socially inappropriate behavior, 
impulsive or careless actions and are linked to right orbital frontal cortex degeneration 
(Olney et al., 2017). Self-awareness declines later on in Frontotemporal dementia to 
where a patient is no longer able to recognize his or her disease state (Olney et al., 2017). 
As the disease progresses, deterioration may favor one part of the brain, making the 
symptoms unique from patient to patient. Right temporal atrophy is associated with 
behavioral changes, while left temporal lobe atrophy is associated with language 
deficiencies (Olney et al., 2017). In the first 5-7 years after diagnosis of right 
frontotemporal dementia, symptoms of disinhibition increase and food preference may 
change, leading to weight gain (Olney et al., 2017). On the other hand, left 
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frontotemporal dementia is much slower to progress, and so a patient may live a dozen 
years after onset (Olney et al., 2017). In left frontotemporal dementia, the semantic 
knowledge of the patient is where the most dramatic decline is seen, and severe language 
impairments (called “primary progressive aphasia”) manifest in the first 2 years of onset 
(Olney et al., 2017). Many patients with left frontotemporal dementia become non-verbal 
in the latest stages of the disease (Olney et al., 2017). 
 
CHAPTER FOUR 
 
DEMENTIA AND HUNTINGTON’S DISEASE 
 
 
What it is and how it differs 
 In 1872, a 22-year-old American doctor named George Huntington wrote a paper 
called On Chorea, describing a hereditary disorder that would later be known as 
Huntington’s Chorea, after the paper was published in the Medical and Surgical Reporter 
of Philadelphia (Phillips et al., 2001). Huntington’s disease (HD) is a progressive 
neurodegenerative disease that has been found to be caused by a glutamine repeat 
expansion in mutation huntingtin (mHtt) (Ahmed et al., 2015). This mutation causes 
profound neurodegeneration, leading to clinical symptoms of dementia with motor 
abnormalities, passed down as an autosomal dominant disorder (Ahmed et al., 2015). The 
effects of this disease manifest mainly in the striatum, which results in the dysfunction 
and death of striatal medium spiny neurons (Ahmed et al., 2015). HD dementia (HDD) is 
widely compared to Alzheimer’s disease due to a majority of similar symptoms; 
however, they are not identical and can be easily differentiated during a diagnosis. Those 
with HDD will likely display symptoms of attention deficit, cognitive slowing, impaired 
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planning and problem solving, and visuoperceptual and construction deficits (Peavy et 
al., 2010).  
 
 
Specific Risks 
 
 The biggest risk factor of Huntington’s disease (HD) is its dominant genetic 
transmission (Myers, 2004). In fact, descendants of HD carriers have a 50% chance of 
developing the disease, with the average onset occurring around age 40 (Myers, 2004). It 
is inevitable that a child who inherits the gene will eventually develop the disease with 
time (Myers, 2004). There is a grey area as to whether some carriers will develop 
Huntington’s disease, depending on the carrier’s trinucleotide repeat, as HD is a 
trinucleotide repeat disorder (Myers, 2004). There is an overexpression of CAG repeats 
in the Huntington’s disease gene, and the total number of this repeat present in a carrier 
determines their likelihood of developing symptoms themselves (Myers, 2004). A typical 
amount of these repeats in a person without the gene are 26 or less, whereas repeats of 40 
or more are associated with clinical disease expression (Myers, 2004). However, some 
carriers with 36 to 39 repeats have the possibility of developing the disease, but typically 
any amount of repeats seen between 27 and 39 are usually associated with parental 
transmission (Myers, 2004). Gender of the carrier plays a role in how the disease is 
passed on (Myers, 2004). A disproportionate number of cases with onset before the age 
of 21 had inherited the HD gene from affected fathers, as opposed to maternal 
transmission, in which case cases develop later in life (Myers, 2004). This is explained by 
meiotic instability of the repeat in paternal transmission, which has the propensity toward 
larger repeat expansion, as opposed to possible meiotic instability seen in maternal 
transmission (Myers, 2004). This larger size of HD repeats seen in paternal transmission 
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is why a much larger proportion of offspring who express the gene manifests much 
earlier in life than those of the maternal germline (Myers, 2004).  
 
 
Diagnosis and Treatment 
 
 The diagnosis of HD is initially diagnosed through simple genetic testing, as 
Huntington’s disease is an inherited disease (Myers, 2004).  However, early diagnosis of 
dementia within this disease is extremely important for assessing a patient’s progression 
and developing a treatment plan to alleviate symptoms (Peavy et al., 2010).  Testing for 
HD occurs under three circumstances including a confirmation diagnosis, predictive 
testing of a person hereditarily at risk, and prenatal testing (Myers, 2004).  Predictive 
testing is often used to decide one’s chances of developing certain characteristics of the 
disease, such as dementia, but this, of course, is not definitive (Myers, 2004).  It is 
essential to look out for any sign of cognitive impairment in Huntington’s disease, as an 
early diagnosis of HDD provides a marker for disease progression, a better understanding 
of any behavioral changes the patient experiences, and the ability to gain access to 
psychosocial and financial resources to compensate for functional impairment (Peavy et 
al., 2010).  Treatments for Huntington’s are only able to compensate for some symptoms 
(Myers, 2004). Although Huntington’s disease is highly researched, there are currently no 
treatments available for preventing or delaying the onset of this disease (Myers, 2004). 
 
Progression 
 
 The progression of Huntington’s disease differs from other forms of dementia 
because it is a relatively early onset and it is slow progressing. Memory decline happens 
over time but has been shown to develop relatively later than other forms of dementia 
(Peavy et al., 2010).  Many studies that assess the progression of Huntington’s disease 
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focus on surveying functional impairment such as “deficits in psychomotor speed, 
attention and executive functions, and visuospatial abilities, as well as motor skills 
coupled with times visual tracking and demographic variables” (Peavy et al., 2010, p. 
1163-1164). A person’s functional ability during the progression of Huntington’s disease 
varies greatly from person to person, with the most varying symptom being functional 
ability, followed closely by measures of attention and initiation (Peavy et al., 2010). In 
order to ensure as much independence as possible in a person with Huntington’s disease, 
early diagnosis is key, as the disease is slow-progressing and a person with early 
Huntington’s disease can live independently for years after a diagnosis (Peavy et al., 
2010). The first sign of dementia in Huntington’s disease is a change in the patient’s 
processing speed, which is first affected before a memory deficit onset (Peavy et al., 
2010). After the initial onset of Huntington’s disease, the average survival time of a 
patient with Huntington’s disease is between 17 and 20 years (Myers, 2004). 
 
 
CHAPTER FIVE 
 
KORSAKOFF’S SYNDROME 
 
 
What it is and how it differs 
 The name Korsakoff’s syndrome (KS) comes from Sergei Korsakoff, a Russian 
neuropsychiatrist who was the first to discuss a comprehensive interpretation of the 
syndrome in a succession of documents published between the years of 1887 and 1891 
(Arts et al., 2017). In these, Korsakoff interpreted findings that the syndrome was 
typically linked to peripheral nerve inflammation, also known as alcoholic polyneuritis, 
and recognized that the disease developed from a toxin. And so, Korsakoff termed the 
syndrome “polyneuritic psychosis or cerebropathia psychica toxaemica” (Arts et al., 
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2017, p. 2876). The term was later changed to Korsakoff’s syndrome by the German 
psychiatrist Friedrich Jolly (Arts et al., 2017). It was later discovered by the German 
neurophsychiatrist Karl Bonhoeffer that KS had a direct relation to another syndrome 
called Wernicke encephalopathy (WE), which results from thiamine deficiency in the 
same way that KS does. Bonhoeffer observed that all patients who survived the WE stage 
advanced to KS as a residual syndrome (Arts et al., 2017). “KS is a largely irreversible 
residual syndrome, caused by severe thiamine deficiency and occurring after incomplete 
recovery from a Wernicke encephalopathy, predominantly in the context of alcohol abuse 
and malnutrition, characterized by an abnormal mental state in which episodic memory is 
affected out of all proportion to other cognitive functions in an otherwise alert and 
responsive patient, whose psychological makeup may be further distinguished by 
executive dysfunction, flattened affect, apathy, lack of illness insight, and possibly by 
fantastic confabulations in the early stage” (Arts et al., 2017, p. 2877). 
 
Specific Risks 
 
 The main risk factor for developing Karsakoff’s syndrome (KS) is a thymine 
deficiency, which is malnourishment that can arise from many different environmental 
factors (Arts et al., 2017). Alcoholism is thought to be the main cause of this deficiency 
and is the most common factor known to lead to KS (Arts et al., 2017). There is no 
evidence, however, for any other reasoning behind alcoholism leading to KS (Arts et al., 
2017). Other factors that can lead to a deficiency in thymine include hyperemesis 
gravidarum, starvation, certain gastrointestinal diseases, AIDS, and bariatric surgery 
recovery (Arts et al., 2017). Korsakoff’s syndrome is likely always developed after 
Wernicke encephalopathy (WE) if the patient lives long enough (Arts et al., 2017). The 
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only uncertainty that comes with this assumption is that WE is easily overlooked, making 
a person with KS unaware of the preceding undiagnosed WE (Arts et al., 2017). In a 
paper published by Arts et al., the writers explain that “severe alcohol abuse certainly 
contributes to the development of WE: the high-calorie content of alcohol suppresses the 
feeling of hunger and favors malnutrition, the combustion of alcohol requires extra 
thiamine pyrophosphate (a co-enzyme in energy-bound processes), alcoholic 
gastroenteritis impairs the absorption of thiamine, alcoholic liver diseases reduces 
thiamine storage in this organ, and alcohol may impair the utilization of thiamine” (2017, 
p. 2880).   
 
Diagnosis and Treatment 
 
 Diagnosis of Korsakoff’s syndrome is different from many other dementias as it is 
not hereditary, and it is the result of WE. WE can be clearly diagnosed with 
neuroimaging and can help support a later clinical diagnosis of KS disease (Arts et al., 
2017). The diagnosis of Karsakoff’s syndrome verifies a chronic state of the condition, 
rather than the acute state of WE. Symptoms that are looked for in a diagnosis of KS 
include dietary deficiencies, oculomotor abnormalities, cerebellar dysfunction, altered 
memory state and/or mild memory impairment (Arts et al., 2017). Although thymine 
replacement therapy has been proven to be effective for WE, KS is treated differently 
(Arts et al., 2017). Since KS is a chronic condition, its treatment is more focused on 
lessening dementia symptoms, improving skills that remain, and subduing symptoms that 
interfere with the patient’s normal activity (Arts et al., 2017). Though there is current 
research in medications such as clonidine, fluvoxamine, reboxetine, and rivastigmine for 
the treatment of Karsakoff’s syndrome, there has been no treatment proven to be effective 
in delaying the disease (Arts et al., 2017). Any treatments given will be focused solely on 
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minimizing the patient’s symptoms. 
 
Progression 
 
 KS is the progression of WE, which develops most often from thiamine 
deficiency. Once a person is diagnosed with WE, it is fairly simple to treat and recover 
from with the use of thiamine replacement treatment (Arts et al., 2017). This can happen 
in a few days to weeks if diagnosed and treated early on (Arts et al., 2017). However, if a 
patient does not get treatment and have a consistent thiamine deficiency, their disease 
becomes persistent and incurable (Arts et al., 2017). This is when they are diagnosed with 
Korsakoff’s syndrome. Korsakoff’s syndrome cannot be treated and this is the point in 
progression where a patient begins to experience an unalterable cognitive decline due to 
permanent damage in the cerebellum (Arts et al., 2017). According to Arts et al., the 
progression of WE to KS in alcoholics (the most common risk factor group of KS) has 
been proposed to be as much as 85% of cases, with most of these patients develop 
“clinically obvious memory impairment” (Arts et al., 2017, p. 2881). In the later stages of 
KS, it has been recorded that many of the longest living patients end up with residual 
syndromes of dementia such as Alzheimer’s disease. Many have also experienced other 
non-dementia related forms of brain damage that manifest as a result of long-term alcohol 
abuse (Arts et al., 2017). 
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CHAPTER SIX 
 
LEWY BODY DEMENTIA 
 
 
What it is and how it differs 
 Dr. Friedrich Lewy discovered Lewy body presence in neurons in 1912 while 
working as a neuropathologist of Parkinson’s disease in the laboratory of Dr. Alois 
Alzheimer; however, it was not until the 1990s that the cause of these formations could 
be explained (Sanford, 2018). It was discovered that the misfolding of α-synuclein 
protein causes the formation of Lewy bodies in the nervous system and though the role of 
α-synuclein is not evident, it is thought to normally function in cell membrane 
remodeling at neuron terminals (Sanford, 2018). Dementia with Lewy bodies (DLB) is 
the second most common neurodegenerative dementia, after Alzheimer’s disease 
(Sanford, 2018). DLB stems from the development of Lewy bodies, which contain 
aggregations of misfolded α-synuclein (Sanford, 2018). These are eventually deposited in 
areas of the nervous system, causing neuronal cell death and leading to clinically 
ostensible symptoms (Sanford, 2018). Lewy body dementia is an “umbrella” term that 
encompasses dementia with Lewy bodies (DLB) and Parkinson’s disease with dementia 
(PDD), which have several common symptoms (Sanford, 2018, p. 603). Moreover, DLB 
and PDD are almost indistinguishable from one another in their final stages (Sanford, 
2018). Each disease progression is the consequence of the aggregation of α-synuclein into 
Lewy bodies but is clinically differentiated by the location of their Lewy body deposits 
(Sanford, 2018).  
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Specific Risks 
 
 The accumulation of overexpressed protein oligomers of α-synuclein form the 
Lewy bodies associated with Lewy body dementia (Sanford, 2018). Lewy bodies tend to 
aggregate in two distinct ways in this disease. Some will deposit predominantly in the 
cytoplasm of neurons and lead to multiple system atrophy, while others will deposit in 
the cytoplasm of both glial cells and neurons (Sanford, 2018). These formations and 
accumulations lead to mitochondrial mutilation and disintegration, eventually provoking 
the cascade of cell death, also referred to as apoptosis (Sanford, 2018). This disease 
progression is estimated to originate in the enteric nervous system and progress into the 
central nervous system, particularly through the vagus nerve, and then into the brain stem 
and higher cortical regions. The propagation of Lewy bodies in Lewy body dementia is 
considered to follow a comparable pattern to the one suggested for Parkinson’s disease 
(Sanford, 2018). Researchers have not been able to clarify why α-synuclein has an initial 
tendency to disrupt neurons in the vagus nerve, olfactory nerve, and brainstem nuclei; 
however, the accumulation of Lewy bodies in these locations lead to the generic 
symptoms seen early on in the disease progression. Some examples of these symptoms 
include anosmia resulting from olfactory nerve cell death and constipation as a result of 
vagus nerve cell death (Sanford, 2018). One of the earliest indicators of onset is rapid eye 
movement (REM) sleep behavior disorder (RBD), a symptom that can arise years before 
a Lewy body dementia diagnosis is made. This symptom is the result of Lewy body 
buildup in the hypothalamus and reticular activation system (Sanford, 2018). 
 Following Alzheimer’s disease, Lewy body dementia is the second most common 
neurodegenerative dementia, affecting 1.4 million Americans. Its biggest risk factor is 
age, as most patients with Lewy body dementia are not diagnosed until around ages 70-
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85 years (Sanford, 2018). Gender has proven to be a risk factor for the disease as well as 
it is estimated that 70% of diagnosed patients are male (Sanford, 2018). Besides age and 
gender, other risk factors to take into account are possible genetic mutations, even though 
Lewy body dementia is known to occur sporadically. Yet, there are a few mutual genetic 
mutations found in diseased patients, which appear in the leucine-rich receptor kinase 2 
(α-synuclein) and glucocerebrosidase A genes (Sanford, 2018).  
 
Diagnosis and Treatment 
 
 Dementia with Lewy bodies is commonly underdiagnosed and misdiagnosed 
(Sanford, 2018). The common clinical diagnosis will assess for any deficits in motor 
function, changes in behavior, mood disorders, and cognitive impairment (Sanford, 
2018). However, many of these symptoms overlap with those of other dementias 
(Sanford, 2018). The overlap continues into neurological diagnosis, as well, as half of 
Alzheimer’s diagnoses are found to have some degree of α-synuclein pathology in 
addition to the anticipated pathological findings (Sanford, 2018). Clinically, it is thought 
that these overlaps worsen symptoms, but this has not been verified, as there is a 
discrepancy in the number of actual cases of DLB as clinical diagnoses differ largely 
from post mortem diagnoses (Sanford, 2018). An autopsy after death is the only way to 
make a definite diagnosis of DLB, and even then, it is hard to determine a primary 
diagnosis when overlapping conditions are present (Sanford, 2018).   
 Treating this disease has proven to be trivial. There are no disease-modifying 
treatments for DLB, only treatments that help to lessen a patient’s symptoms (Sanford, 
2018). However, because of the multiple symptoms of this disease, oftentimes multiple 
medications are needed, which often have negative effects on opposing symptoms 
(Sanford, 2018). Because one drug may improve a symptom while worsening another, it 
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is recommended that a patient is introduced to only one medication at a time, making 
treatment a cumbersome process for the patient (Sanford, 2018). One symptom that is 
recommended to be treated non-pharmacologically is the presence of visual 
hallucinations, which is common in patients with DLB (Sanford, 2018). Because of 
neuroleptic sensitivity of many with DLB, medications are not given for this symptom, 
except in severe cases (Sanford, 2018). 
 
Progression 
 
 Development of Lewy bodies in various nuclei in the reticular activating system 
of the brainstem can be seen in initial progression stages of Lewy body dementia, 
manifesting months to even years before the condition is diagnosed (Sanford, 2018). As 
the disease progresses, a patient may experience varying symptoms including 
visuospatial deficits, neuroleptic sensitivity, changes in mood, autonomic dysfunction, 
and recurrent falls (Sanford, 2018). This is when a patient will begin experiencing a lack 
of independence as these issues complicate normal activities such as walking and driving 
(Sanford, 2018). Increased cognitive impairment develops, and certain symptoms may 
get worse with medications, such as Parkinson-like motor deficits (Sanford, 2018). Mood 
symptoms occur, as well, with the course of this disease and can manifest in many ways 
including depression, apathy, and anxiety, as well as paranoia, which has been known to 
occur in those who experience visual hallucinations (Sanford, 2018). Dementia with 
Lewy bodies is a constantly progressing neurodegenerative disease for which there is no 
treatment that is able to affect progression, so a patient will continually progress with this 
disease until death (Sanford, 2018). The decline of DLB is faster than that of 
Alzheimer’s, with patients surviving an average of 4.7 years after initial diagnosis 
(Sanford, 2018). 
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CHAPTER SEVEN 
 
DEMENTIA AND PARKINSON’S DISEASE 
 
 
What it is and how it differs 
 Parkinson’s disease was described in multiple patient documents during the 
1700s, but it was not until a man by the name of James Parkinson conducted his medical 
description of the disease in 1817 that Parkinson’s was officially defined (Goetz, 2011). 
Further research on the disease was conducted in the mid-1800s by Jean-Martin Charcot, 
who influenced Parkinson’s research by comparing the disease with another: multiple 
sclerosis, along with other disorders that are characterized by tremors (Goetz, 2011). 
Parkinson’s disease (PD) and dementia (PDD) greatly decrease a patient’s quality of life 
and are often labeled as death sentences, as they decrease a person’s ability to remain 
independent (Holden et al., 2016). Though this disease has been thoroughly researched 
and is increasingly common, the pathogenic pathways of PD remain poorly understood 
(Yang et al., 2018). PD is, in fact, the second-most common neurodegenerative disease 
(Yang et al., 2018). Although the pathophysiological signatures are evident in numerous 
parts of the brain, the characterizing symptoms of PD which include bradykinesia, 
rigidity, abnormal posture, and resting tremor, actually stem predominantly from 
progressive loss of DA neurons in the substantia nigra pars compacta (SNc) of the brain 
(Yang et al., 2018).  
 
Specific Risks 
 
 Parkinson’s disease is the number two most common neurodegenerative illness, 
following Alzheimer’s disease (Holden et al., 2016). An estimated 5 million people are 
living with this disease, a population that is expected to double in the next 20 years 
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(Holden et al., 2016). Parkinson’s disease with dementia, or PDD, worsens the clinical 
progression of the disease, decreasing patient independence at a rapid rate (Holden et al., 
2016). Early progression is slow, though, as those who do develop PDD on average were 
not diagnosed until 11 years after a PD diagnosis (Holden et al., 2016). For those who 
live with Parkinson’s disease for 20 years or more, the chances of PDD are estimated to 
increase to as much as 75% (Holden et al., 2016). Although genetic transmission is a 
huge risk in Parkinson’s disease, the biggest risk of PDD is its age of onset (Hanagasi et 
al., 2017). There is a 12-fold increased risk of developing dementia in late-onset of 
Parkinson’s disease compared to those who first experienced symptoms early in life 
(Hanagasi et al., 2017).  
 
Diagnosis and Treatment 
 
 Those who have been diagnosed with Parkinson’s disease are monitored for 
dementia symptoms through cognitive impairment testing and a thorough investigation of 
family history. It is unknown where Parkinson’s disease dementia originates, making it 
difficult to treat  (Yang et al., 2018).  
 Certain changes in cellular processes have been tested to gain insight on the 
possible causes of neuronal depletion: dysregulation of vesicular trafficking, oxidative 
stress, disruption of the autophagy/lysosome pathway, mitochondrial dysfunction, 
endoplasmic reticulum stress, and Ca2+ homeostasis  (Yang et al., 2018). PD has motor 
therapies that can help with the disease’s symptoms, but PDD is much harder to treat, as 
physical therapies are not effective in the dementia population (Holden et al., 2016). 
Treatments for PDD have only marginal therapeutic effects; however, there has been one 
medication that has been approved to specifically treat Parkinson’s disease with dementia 
(Holden et al., 2016). Rivastigmine, a cholinesterase inhibitor, has been approved by the 
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FDA for treatment of this condition but is not able to change the progression of the 
disease, only alleviate its symptoms (Holden et al., 2016). The N-methyl-D-aspartate 
receptor antagonist Memantine is frequently used in PDD patients, as well, and seems to 
have similar effects in lessening Parkinson’s disease and dementia symptoms (Holden et 
al., 2016). 
 
Progression 
 
 The most common misregulated processes in Parkinson’s disease cortical neurons 
are axonal transport, cell adhesion, and mRNA splicing, all of which manifest very early 
on in PD progression, before dementia symptoms (Henderson-Smith et al., 2016). Causes 
of PD/PDD have been associated with differential alternative splicing in the cortex; the 
spread of α-synuclein pathology to the cortex is linked specifically with PDD 
(Henderson-Smith et al., 2016). This is slow progressing and can lead to Parkinson’s 
disease with or without a dementia presence. Age is an important factor in the 
progression of this disease as the older a patient’s Parkinson’s disease manifests, the 
quicker it may progress and the likelihood of dementia presence increases. Stated by 
Henderson-Smith et al., “RNA-seq clearly reveals the underlying differential alternative 
splicing in the posterior cingulate cortex during the course of PD and PDD. Alternative 
splicing of ATXN2, HSPH1, SRRM1, RELA, LRRFIP1, and TRIM9 suggests 
dysregulation of genes within immune and inflammation responses and transcription and 
RNA processing” (2016, p. 6). In this paper, Henderson-Smith et al. describe the 
overexpression of genes CSF3 and SELE, in both Parkinson’s disease with dementia and 
without, occurring prior to pathological changes that occur in the posterior cingulate 
cortex, suggesting there likely being an early role of immune induction in the progression 
of Parkinson’s disease, as well (Henderson-Smith et al., 2016, p. 6). 
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CHAPTER EIGHT 
 
VASCULAR DEMENTIA 
 
 
What it is and how it differs 
 Vascular dementia (VD) studies can be traced back as far as the 1600s when 
Thomas Willis described the disease in 1672. However, due to the inability to diagnose 
such a disease in a living patient, the typical diagnosis for vascular dementia for centuries 
was conjured up to be nothing but “brain congestion,” due to the “effects of untreated 
hypertension,” along with other diagnoses such as stroke, anxiety, and cognitive decline 
(Román, 2003, p. 11). The modern history of vascular dementia was initiated in 1894 
when Otto Binswanger and Alois Alzheimer separated vascular dementia from dementia 
paralytica caused by neurosyphilis, which leads to major discoveries and studies of 
vascular dementia decades later, in the 1960s, when the seminal neuropathological and 
clinical analyses of the New Castle school in England introduced the modern era of 
vascular dementia (Román, 2003). Vascular cognitive impairment distinguishes the 
diverse nature of the influence of vascular pathology to dementia, as well as other 
different subtypes (O’Brien & Thomas, 2015). Though well researched, finding the exact 
contribution of cerebrovascular pathology to cognitive decline and dementia has proven 
to be exceptionally challenging. While it seems evident that cerebrovascular disease 
causes pathological damage and alters cognition, the actual cause remains black-boxed 
(O’Brien & Thomas, 2015). This is, in part, because the cognitive changes of vascular 
dementia are much more inconsistent than that of other disorders such as Alzheimer's 
disease, and are exceedingly dependent on the particular neural substrates affected by 
vascular pathology. Symptoms of VD that are most commonly seen, though, include 
attention deficits, information processing deficits, and executive function deficits, due to 
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the interrupting of frontostriatal circuits (O’Brien & Thomas, 2015).  
 
Specific Risks 
 
 Vascular events are the second highest cause of dementia; the first is Alzheimer’s 
(O’Brien & Thomas, 2015). The risk of developing dementia due to a vascular event 
increases greatly with age, and the number of cases has a history to double approximately 
every 5.3 years (O’Brien & Thomas, 2015). In their paper of vascular dementia research, 
O’Brien and Thomas explain that “vascular pathology has a heterogeneous nature in 
which large vessel atherosclerosis and small vessel arteriosclerosis can lead to cortical 
and subcortical infarcts, subinfarct ischaemic lesions (microinfarcts in grey matter and 
white matter lesions), and large and small cerebral hemorrhages (microbleeds)” (2015, p. 
1675).
 
These events can take place in a variety of areas in the brain and still lead to a 
vascular dementia diagnosis (O’Brien & Thomas, 2015). Other events leading to vascular 
disease include heart disease, atrial fibrillation, high cholesterol, high homocysteine 
concentrations, diabetes, and obesity; however, vascular dementia is most often seen in 
post-stroke patients (O’Brien & Thomas, 2015). It is estimated that approximately 15-
30% of stroke patients will develop dementia within 3 months following the event 
(O’Brien & Thomas, 2015).  The prolonged instance of delayed dementia occurring in 
those who have had a stroke is estimated to be about 20-25% (O’Brien & Thomas, 2015). 
 
Diagnosis and Treatment 
 
 For the diagnosis of vascular dementia, a standard dementia screening test is not 
enough to pinpoint this specific condition (O’Brien & Thomas, 2015). There are specific 
screening tests that can more specifically diagnose vascular dementia: for this, the 
Montreal cognitive assessment scale and the vascular dementia assessment scale are used 
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for a more accurate diagnosis (O’Brien & Thomas, 2015). To come to a definitive 
diagnosis of vascular dementia, a CT scan or MRI is needed to correctly compare brain 
activity with clinical symptoms (O’Brien & Thomas, 2015). The CT scans are able to 
display infarcts and extensive white matter lesions of the brain, and an MRI examination 
can precisely show the location and extent of cerebrovascular disease, but a diagnosis can 
be completed with a simple CT scan when compared with clinical symptoms (O’Brien & 
Thomas, 2015). There is little explanatory research on the mechanisms of vascular 
dementia onset and progression, so there are no approved treatments for this specific 
condition (O’Brien & Thomas, 2015). Though there have been minor cognitive benefits 
seen with cholinesterase inhibitors and memantine, these medications are not encouraged 
due to a higher risk than benefit payoff. There are currently clinical trials on possible 
vascular dementia treatments including calcium channel blockers and other agents that 
target endothelial function or the renin angiotensin system, but nothing has yet seen 
approval (O’Brien & Thomas, 2015). 
 
Progression 
 
 Studies on the progression of vascular dementia have been most commonly done 
in post-stroke patients, where brain images of those with and without dementia do not 
display any notable differences (O’Brien & Thomas, 2015). There have, however, been 
several studies that have reported: “lacunes, strategic infarcts, substantial burden of white 
matter lesions” consistent in many vascular dementia cases, which presented one or 
multiple of these (O’Brien & Thomas, 2015, p. 1673). The presence of white matter 
lesions are a common indicator of subcortical vascular disease, which presents itself 
without dementia in its early stages (O’Brien & Thomas, 2015). It is worth pointing out 
that many of these patients who do experience dementia in this disease more likely than 
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not, will be experiencing a form of mixed dementia, of which is to say its cause is not 
vascular, though it may contribute to progression (O’Brien & Thomas, 2015). Vascular 
dementia arises in the top 10% of the most severe cases of those with a deterioration of 
vascular origin (O’Brien & Thomas, 2015). As the disease progresses, assessments must 
be done carefully as white matter lesions can indicate other non-ischaemic causes, but it 
is safe to draw conclusions of vascular origin in the oldest population (diagnosis at 75 
years of age or older) since dementia is commonly more severe in older patients. This 
late-onset of cerebrovascular disease may not display dementia immediately, but will 
likely progress quickly, often showing signs of cognitive and functional impairment 
within three years of onset (O’Brien & Thomas, 2015). Though the pathological 
progression of vascular dementia is not well defined, the burden of the disease typically 
will increase with age, similar to other forms of dementia (O’Brien & Thomas, 2015). It 
is in the best interest of the patient and his or her caregivers to get the earliest diagnosis 
possible in order to assess and manage the progression of this form of dementia and to 
preserve the patient’s independence as much as possible, mimicking care given to those 
with an Alzheimer’s diagnosis, as the progression of AD is much more commonly 
assessed (O’Brien & Thomas, 2015). 
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